Drug Profile


Alternative Names: BRIVIACT; BRIVLERA; RIKELTA; UCB-34714

Latest Information Update: 27 Apr 2017

Price : $50

At a glance

  • Originator UCB
  • Class Antiepileptic drugs; Neuroprotectants; Non-opioid analgesics; Nootropics; Pyrrolidinones; Small molecules
  • Mechanism of Action Sodium channel antagonists; SV2A protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myoclonic epilepsies
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Epilepsy
  • Discontinued Myoclonic epilepsies; Postherpetic neuralgia

Most Recent Events

  • 22 Mar 2017 UCB Pharma plans a phase III trial for Epilepsy (Adjunctive treatment) (NCT03083665)
  • 01 Mar 2017 UCB Pharma completes a phase III trial in Epilepsy in USA, Australia, Belgium, Canada, Czech Republic, France, Germany, Hungary, Italy, Spain and Sweden (PO)(NCT00761774)
  • 22 Feb 2017 UCB Biopharma initiates a phase II trial for Epilepsy in USA (IV) (NCT03021018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top